Integrated BioPharma, Inc.
INBP · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $10,816 | $6,013 | $9,883 | $14,919 |
| - Cash | $3,615 | $1,677 | $1,316 | $331 |
| + Debt | $1,015 | $1,798 | $2,672 | $2,055 |
| Enterprise Value | $8,216 | $6,134 | $11,239 | $16,643 |
| Revenue | $54,353 | $50,317 | $50,672 | $56,246 |
| % Growth | 8% | -0.7% | -9.9% | – |
| Gross Profit | $5,562 | $3,884 | $4,061 | $6,552 |
| % Margin | 10.2% | 7.7% | 8% | 11.6% |
| EBITDA | $3,377 | $1,472 | $1,274 | $3,559 |
| % Margin | 6.2% | 2.9% | 2.5% | 6.3% |
| Net Income | $808 | $112 | -$34 | $3,838 |
| % Margin | 1.5% | 0.2% | -0.1% | 6.8% |
| EPS Diluted | 0.026 | 0.004 | -0.001 | 0.12 |
| % Growth | 619.4% | 427.3% | -100.9% | – |
| Operating Cash Flow | $2,065 | $943 | $1,232 | $4,091 |
| Capital Expenditures | -$191 | -$553 | -$116 | -$486 |
| Free Cash Flow | $1,874 | $390 | $1,116 | $3,605 |